Essential thrombocythemia (ET) is a chronic Philadelphia-negative myeloproliferative neoplasm that has its main involvement in the megakaryopoietic lineage, generating sustained thrombocytosis in peripheral blood and an increase in the number of mature megakaryocytes in the bone marrow. In addition to marked thrombocytosis, it is characterized by increased thrombotic or hemorrhagic risk and the presence of constitutional symptoms. Patients with ET have a low but known risk of disease progression to myelofibrosis and/or acute leukemia. The diagnosis is made based on the 2016 WHO criteria. At present, available treatments for patients with ET are mainly aimed at minimizing the risk of thrombosis and/or bleeding.

Download full-text PDF

Source
http://dx.doi.org/10.24875/GMM.M22000803DOI Listing

Publication Analysis

Top Keywords

essential thrombocythaemia
4
thrombocythaemia essential
4
essential thrombocythemia
4
thrombocythemia chronic
4
chronic philadelphia-negative
4
philadelphia-negative myeloproliferative
4
myeloproliferative neoplasm
4
neoplasm main
4
main involvement
4
involvement megakaryopoietic
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!